MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: a meta-analysis

References

• Burnett A, Wetzler M, Löwenberg B. (2011). Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487–94
   PubMed Web of Science ®Google Scholar
• Cascorbi I. (2011). P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 201:261–83
   PubMedGoogle Scholar
• Chauhan PS, Bhushan B, Singh LC, et al. (2012). Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy. Exp Mol Pathol 92:44–9
   PubMed Web of Science ®Google Scholar
• Cheson B, Bennett J, Kopecky K, et al. (2003). Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642–9
   PubMed Web of Science ®Google Scholar
• Cochran WG. (1954). Some methods for strengthening the common χ2 tests. Biometrics 10:417–51
   Web of Science ®Google Scholar
• Dahl GV, Lacayo NJ, Brophy N, et al. (2000). Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. J Clin Oncol 18:1867–75
   PubMedGoogle Scholar
• de Lima M, Strom S, Keating M, et al. (1997). Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood 90:4719–24
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. (1986). Meta-analysis in clinical trials. Control Clin Trials 7:177–88
   PubMed Web of Science ®Google Scholar
• Estey EH. (2002). Treatment of acute myelogenous leukemia. Oncology 16:343–52
   PubMed Web of Science ®Google Scholar
• Estey E, Döhner H. (2006). Acute myeloid leukaemia. Lancet 368:1894–907
   PubMed Web of Science ®Google Scholar
• Fujimaki S, Funato T, Harigae H, et al. (2002). Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia. Clin Chem 48:811–17
   Google Scholar
• Gottesman MM, Fojo T, Bates SE. (2002). Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48–58
   PubMed Web of Science ®Google Scholar
• Gruber A, Vitols S, Norgren S, et al. (1992). Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia. Br J Cancer 66:266–72
   PubMed Web of Science ®Google Scholar
• Gsur A, Zöchbauer S, Götzl M, et al. (1993). MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update. Leuk Lymphoma 12:91–4
   PubMed Web of Science ®Google Scholar
• Guenova ML, Balatzenko GN, Nikolova VR, et al. (2010). An anti-apoptotic pattern correlates with multidrug resistance in acute myeloid leukemia patients: a comparative study of active caspase-3, cleaved PARPs, Bcl-2, Survivin and MDR1 gene. Hematology 15:135–43
   PubMed Web of Science ®Google Scholar
• Harbord RM, Egger M, Sterne JA. (2006). A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25:3443–57
   PubMed Web of Science ®Google Scholar
• Hart SM, Ganeshaguru K, Scheper RJ, et al. (1997). Expression of the human major vault protein LRP in acute myeloid leukemia. Exp Hematol 25:1227–32
   PubMed Web of Science ®Google Scholar
• Hartmann G, Kim H, Piquette-Miller M. (2001). Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines inmice. Int Immunopharmacol 1:189–99
   PubMed Web of Science ®Google Scholar
• Hedges LV, Olkin I. (1985). Statistical methods for meta-analysis. Orlando: Academic Press
   Google Scholar
• Higgins JP, Thompson SG. (2002). Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–58
   PubMed Web of Science ®Google Scholar
• Ho MM, Hogge DE, Ling V. (2008). MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp Hematol 36:433–42
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. (2011). SEER cancer statistics review, 1975--2008. Bethesda (MD): National Cancer Institute
   Google Scholar
• Huang Y. (2007). Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 26:183–201
   PubMed Web of Science ®Google Scholar
• Huh HJ, Park CJ, Jang S, et al. (2006). Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J Korean Med Sci 21:253–8
   PubMed Web of Science ®Google Scholar
• Hunault M, Zhou D, Delmer A, et al. (1997). Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann Hematol 74:65–71
   PubMed Web of Science ®Google Scholar
• Hur EH, Lee JH, Lee MJ, et al. (2008). C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia. Leuk Res 32:1601–4
   PubMed Web of Science ®Google Scholar
• Illmer T, Schuler US, Thiede C, et al. (2002). MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955–62
   PubMed Web of Science ®Google Scholar
• Kim DH, Park JY, Sohn SK,et al. (2006). Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 118:2195–201
   PubMed Web of Science ®Google Scholar
• Kitsios GD, Zintzaras E. (2009). Genomic convergence of genome-wide investigations for complex traits. Ann Hum Genet 73:514–19
   PubMed Web of Science ®Google Scholar
• Leith CP, Kopecky KJ, Chen IM, et al. (1999). Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94:1086–99
   PubMed Web of Science ®Google Scholar
• Lin SF, Huang SM, Chen TP, et al. (1995). MDR1 gene expression in acute myeloid leukemia: clinical correlation. J Formos Med Assoc 94:111–16
   PubMedGoogle Scholar
• Monzo M, Brunet S, Urbano-Ispizua A, et al. (2006). Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 107:4871–9
   PubMed Web of Science ®Google Scholar
• Petti MC, Tafuri A, Latagliata R, et al. (2003). High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. Ann Hematol 82:476–80
   PubMed Web of Science ®Google Scholar
• Sato H, Preisler H, Day R, et al. (1990). MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol 75:340–5
   PubMed Web of Science ®Google Scholar
• Schaich M, Harbich-Brutscher E, Pascheberg U, et al. (2002). Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Haematologica 87:455–64
   PubMed Web of Science ®Google Scholar
• Tallman MS, Gilliland DG, Rowe JM. (2005). Drug therapy of acute myeloid leukemia. Blood 106:1154–63
   PubMed Web of Science ®Google Scholar
• Tan Y, Li G, Zhao C, et al. (2003). Expression of sorcin predicts poor outcome in acute myeloid leukemia. Leuk Res 27:125–31
   Google Scholar
• Trikalinos TA, Salanti G, Zintzaras E, Ioannidis JP. (2008). Meta-analysis methods. Adv Genet 60:311–34
   PubMed Web of Science ®Google Scholar
• Trnková Z, Bedrlíková R, Marková J, et al. (2007). Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia. Neoplasma 54:383–90
   PubMed Web of Science ®Google Scholar
• Van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, et al. (2007). CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 86:329–37
   PubMed Web of Science ®Google Scholar
• Van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, et al. (2006). ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther 80:427–39
   PubMed Web of Science ®Google Scholar
• Venditti A, Del Poeta G, Maurillo L, et al. (2004). Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. Haematologica 89:934–9
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Valk PJ. (2010). Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia. Cancer Treat Res 145:67–83
   PubMedGoogle Scholar
• Wells RJ, Odom LF, Gold SH, et al. (1994). Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. Med Pediatr Oncol 22:244–9
   PubMedGoogle Scholar
• Whitehead A. (2002). Meta-analysis of controlled clinical trials. Chichester, UK: John Wiley & Sons, Ltd
   Google Scholar
• Xu D, Areström I, Virtala R, et al. (1999). High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone. Br J Haematol 106:627–33
   PubMed Web of Science ®Google Scholar
• Zintzaras E. (2010). The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies. Stat Appl Genet Mol Biol 9: Article 21
   Google Scholar
• Zintzaras E. (2012). The power of generalized odds ratio in assessing association in genetic studies with known mode of inheritance. J Appl Stat 39:2569–81
   Web of Science ®Google Scholar
• Zintzaras E, Ioannidis JP. (2005). Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28:123–37
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Lau J. (2008a). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 61:634–45
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Lau J. (2008b). Trends in meta-analysis of genetic association studies. J Hum Genet 53:1–9
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Kitsios GD. (2009). Synopsis and synthesis of candidate-gene association studies in chronic lymphocytic leukemia: the CUMAGAS-CLL information system. Am J Epidemiol 170:671–8
   Google Scholar
• Zintzaras E, Doxani C, Ziogas DC, et al. (2011). Bone mineral density and genetic markers involved in three connected pathways (focal adhesion, actin cytoskeleton regulation and cell cycle): the CUMAGAS-BMD information system. Biomarkers 16:698–708
   Web of Science ®Google Scholar